Table 5. Distribution of modified GPS 2 in patients with benign and malignant fGGOs before and after PSM.

	Before PSM (n = 128)				After PSM (n = 82)
	m2GPS 0, n (%)	m2GPS 1, n (%)	m2GPS 2, n (%)	Total, n	m2GPS 0, n (%)	m2GPS 1, n (%)	m2GPS 2, n (%)	Total, n
Benign, n (%)	17 (33.3%)	18 (35.3%)	16 (31.4%)	51	13 (31.7%)	15 (36.6%)	13 (31.7%)	41
Malignant, n (%)	20 (26.0%)	17 (22.1%)	40 (51.9%)	77	10 (24.4%)	10 (24.4%)	21 (51.2%)	41

fGGOs: focal Ground-glass Opacity.

PSM: propensity score matching.

m2GPS: modified Glasgow prognostic score system 2.